Results: 2

Serological profile of John Cunningham virus (JCV) in patients with multiple sclerosis

Arq. neuropsiquiatr; 76 (9), 2018
ABSTRACT Treatment options for multiple sclerosis (MS) have changed over the last few years, bringing about a new category of drugs with more efficient profiles. However, these drugs have come with a whole new profile of potential adverse events that neurologists have to learn well and quickly. One of th...

Safety of switching from natalizumab straight into fingolimod in a group of JCV-positive patients with multiple sclerosis

Arq. neuropsiquiatr; 74 (8), 2016
ABSTRACT Objective To assess safety of the switch between natalizumab and fingolimod without a washout period. Methods Prospective data on 25 JCV positive patients who underwent this medication switch were collected and analyzed. Results After a median period of nine months from the medication swit...